Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance is a research paper published in Frontiers in Oncology (2022). On theSindex it has a DataRank of 0.432. It has been cited 7 times, with 6 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.312
From this paper's citation signal
Citation Network Contribution
0.120
From 4 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 6 citers.
NCI NIH HHS
Grant: T32 CA009531
NCI NIH HHS
Grant: R01 CA229535
NCI NIH HHS
Grant: P30 CA022453
NCI NIH HHS
Grant: R01 CA174949
NCI NIH HHS
Grant: R21 CA249376
National Institutes of Health
Grant: 3R01CA174949-05S1
Developing targeted therapies for triple-negative breast cancer
National Institutes of Health
Grant: 2T32CA009531-21
Training Program in the Biology of Cancer
National Institutes of Health
Grant: 5R21CA249376-02
Targeting Atg5 in platinum-resistant ovarian cancer
National Institutes of Health
Grant: 5R01CA229535-05
Novel role of APOBEC3 enzymes as key mediators of cisplatin sensitivity through aberrant processing of interstrand crosslinks
Office of Extramural Research, National Institutes of Health
DMC Foundation
Barbara Ann Karmanos Cancer Institute
FWCI
0.73
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals